Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02128919 · ClinicalTrials.gov registry record · NA

Transcranial Direct Current Stimulation (tDCS) As A Treatment For Cigarette Craving and Cognitive Deficits in Schizophrenic

A NA study, sponsored by Nathan Kline Institute for Psychiatric Research.

Completed
Registry status
NA
Development phase
33
Enrollment target

NCT02128919 is a NA study that has completed, run by Nathan Kline Institute for Psychiatric Research. The registered enrollment target is 33 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02128919, a NA study, has completed, sponsored by Nathan Kline Institute for Psychiatric Research.

COMPLETED
Registry status
NA
Development phase
33 participants
Enrollment target

Study Summary

This is a study of the effects of tDCS on smoking, craving for cigarettes, cognition, and psychiatric symptoms in schizophrenic patients who are current smokers or have a history of regular cigarette smoking. It assesses smoking with CO monitoring, nicotine and nicotine levels, and craving with QSU scale and response to craving slides. Cognition is measured by MCCB, symptoms are measured by PANSS and hallucination scale. This is a double-blind sham-controlled study with active tDCS 2ma or 20 minutes over 5 days, and sham tDCS for 40 seconds on each sham occasion.

Interventions

  • DEVICE tDCS

Trial Details

FieldValue
Enrollment Target 33 participants
Start Date 2012-04
Est. Completion 2016-12
Phase NA

What the Registry Record Tells You About NCT02128919

The ClinicalTrials.gov registry entry for NCT02128919 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nathan Kline Institute for Psychiatric Research, which has 20 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which tDCS is the first listed.

NCT02128919 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02128919 about?

NCT02128919 is a clinical study titled "Transcranial Direct Current Stimulation (tDCS) As A Treatment For Cigarette Craving and Cognitive Deficits in Schizophrenic". This is a study of the effects of tDCS on smoking, craving for cigarettes, cognition, and psychiatric symptoms in schizophrenic patients who are current smokers or have a history of regular cigarette smoking. It assesses smoking with CO monitoring, nicotine and nicotine levels, and craving with QSU ...

What is the current status of trial NCT02128919?

This trial is currently completed. It is a NA study. The enrollment target is 33 participants. The study started on 2012-04. Estimated completion is 2016-12.

What interventions are being tested in trial NCT02128919?

The interventions under investigation include: tDCS (DEVICE).

Who is sponsoring clinical trial NCT02128919?

This trial is sponsored by Nathan Kline Institute for Psychiatric Research, which has 20 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.